| Affiliation: | 1. Molecular Diagnostics Laboratory, INRaSTES, National Center for Scientific Research “Demokritos”, Athens, Greece;2. General Clinic “IASIS”, Chania, Crete, Greece;3. Laboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Crete, Greece Department of Medical Oncology, School of Medicine, University Hospital of Heraklion, Crete, Greece;4. General Hospital of Heraklion "Venizelio-Pananio", Heraklion, Greece;5. Second Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece;6. Department of Medical Oncology, School of Medicine, University Hospital of Heraklion, Crete, Greece;7. Department of Surgery, School of Medicine, University of Crete, Heraklion, Greece;8. Oncology Unit, Second Department of Surgery, Aretaieion Hospital, National and Kapodistrian University of Athens, Athens, Greece;9. Hellenic Oncology Research Group (HORG), Athens, Greece;10. Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece |
| Abstract: | Germline BRCA1 and BRCA2 loss-of-function variants have been linked to increased breast and ovarian cancer risk, with more than 5,000 distinct pathogenic variants being reported worldwide. Among individuals of Greek descent, the BRCA1/2 variant spectrum is heterogeneous, but characterized by strong founder effects. As patients from certain geographical regions of Greece (like Crete) were underrepresented in previous studies, we hypothesized that isolated Cretans, a southern Greece islanders' population with distinct demographic, cultural and genetic features, could harbor founder BRCA1/2 mutations. A total of 304 breast or/and ovarian cancer patients of Cretan descent, fulfilling NCCN criteria for genetic testing, were tested by NGS or Sanger sequencing, followed by MLPA. Haplotype analysis was subsequently performed to investigate potential founder effects of recurrent alleles. Overall, 16.5% (50/304) of the tested patients carried 22 different pathogenic variants; 48% in BRCA1, 52% in BRCA2. Three variants, namely two in BRCA2 (Δexons 12 and 13 and c.7806-2A>T) and one in BRCA1 (c.5492del), constituting approximately half (48%) of all detected pathogenic variants, were shown to have a founder effect, with all carriers sharing common haplotypes. Remarkably, these variants were confined to Cretans and have not been identified in other regions of Greece. The high prevalence of specific BRCA1/2 pathogenic variants among Cretans, provides the possibility of cost- and time-efficient screening of the Cretan population. Integrating this knowledge in local public health services may have a significant impact on cancer prevention, and may serve as a starting point for the implementation of testing on a population level. |
